Portola Pharmaceuticals has secured $89m in preferred stock financing to advance its Phase III clinical programme of betrixaban, a once-daily, oral Factor Xa inhibitor.
The funds will also be used to develop PRT064445, a recombinant Factor Xa inhibitor antidote.
Go deeper with GlobalData
The company is planning to commence a Phase III programme in the first half of 2012to trial betrixaban as a way of preventing venous thromboembolism in acutely ill patients.
In collaboration with Biogen Idec, Portola will develop PRT062607, an oral Syk-specific kinase inhibitor in thrombosis.
Biogen Idec will provide Portola with an upfront payment of $45m, which includes $36m in cash and $9m in Portola equity.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
